FCGR3A and B-cell chronic lymphocytic leukemia: TriKE 161519 was recently described by Felices et al. (271) for treatment of chronic lymphocytic leukemia (CLL); this antibody consists of anti-CD19 and anti-CD16 fragments, with an additional IL-15 moiety.